郑州租人睡觉过夜APP哪个好-郑州租人睡觉过夜APP哪个好_首页

在临沧酒店晚上怎么叫服务

Welcome to the official website of Yantai Dongcheng Pharmaceutical Group Co., Ltd!
Stock Code: 002675
Company news
Your current position: home page >> News Center >> Company news
"Dongcheng investment meado signing ceremony and molecular image innovation and transformation seminar" was held
Date [2020-05-26 16:51]【 】Times

           On May 24, 2020, Dongcheng invested in Rice The signing ceremony and molecular image innovation and transformation seminar was successfully held in the 809 conference room of the group headquarters. The main leaders of the group, the shareholder representatives of Mido biology and the management team attended the meeting. At the same time, director Yang Zhi of Beijing Cancer Hospital, director Jiang Ji of Peking Union Medical College Hospital, and some pharmaceutical investment experts were invited to provide suggestions and suggestions for the company's product transformation.

The meeting has two parts: signing ceremony and seminar. During the signing ceremony, Mr. Luo Zhigang, deputy general manager of the company and general manager of Andico profit center, Mr. Yang Lichuan, representative of Nanjing yunmi, Mr. Geng Shuying, representative of Nanjing meianbei, Mr. Zhuang Dajun, representative of Shikang holdings and Mr. Li Xinping, representative of Mido bio, jointly completed the investment intention of Andico's acquisition of Mido The signing of the letter laid a solid foundation for the subsequent merger of Mido biology into Dongcheng pharmaceutical.
In the seminar, Mr. Yang Lichuan, general manager of Mido biology, and Mr. Luo Zhigang, deputy general manager of Mido biology, respectively made a detailed interpretation of the company's situation and the planning and development of the company's nuclear medicine sector. The industry experts and investment experts attending the meeting exchanged and discussed the relevant key issues, which provided guidance for the rapid transformation of the company's nuclear and pharmaceutical products in the future and strengthened the investment The company's future development confidence.
On the occasion of the eighth anniversary of the company's listing, the signing of the letter of intent for the acquisition of Mido by Andico is conducive to the rapid improvement of the company's nuclear drug R & D and transformation platform, making full use of the unique advantages of Mido bio in molecular imaging tracking and nuclear drug transformation, so as to further consolidate the company's market position in the field of nuclear medicine and lay a solid foundation for the company's strategic development.

 

Last article:
Next:
contact us CONTACT US
0535-6391521
Switchboard: 86-535-6391521 / 6391522
Email: zxu @ midatlanticlegends.com
Address: No.7 Changbaishan Road, Yantai Development Zone, Shandong Province
Copyright 2014 Yantai Dongcheng Pharmaceutical Group Co., Ltd. All Rights Reserved Lu ICP Bei 18035060-1